keyword
https://read.qxmd.com/read/34228181/comparative-efficacy-and-safety-of-infliximab-and-its-biosimilars-in-patients-with-rheumatoid-arthritis-presenting-an-insufficient-response-to-methotrexate-a-network-meta-analysis
#1
JOURNAL ARTICLE
Young Ho Lee, Gwan Gyu Song
OBJECTIVE: To assess the relative efficacy and safety of infliximab and its biosimilars in patients with active rheumatoid arthritis (RA) who showed an inadequate response to methotrexate (MTX). METHODS: We performed a Bayesian network meta-analysis combining direct and indirect evidence from randomized controlled trials (RCTs), comparing the efficacy and safety of infliximab biosimilars versus the originator product in patients with active RA despite receiving MTX...
July 6, 2021: Zeitschrift Für Rheumatologie
https://read.qxmd.com/read/34223982/comparative-efficacy-and-safety-of-tumor-necrosis-factor-inhibitors-and-their-biosimilars-in-patients-with-rheumatoid-arthritis-having-an-insufficient-response-to-methotrexate-a-network-meta-analysis
#2
JOURNAL ARTICLE
Young Ho Lee, Gwan Gyu Song
OBJECTIVE: This study aimed to compare the effectiveness and safety of tumor necrosis factor inhibitor (TNFI) biosimilars to TNFI originators in patients with active rheumatoid arthritis (RA) who responded inadequately to methotrexate (MTX). METHODS: We conducted a meta-analysis of randomized controlled trials (RCTs) to compare the effectiveness and safety of TNFI biosimilars to TNFIs in patients with RA who had not responded adequately to MTX. RESULTS: A total of 18 RCTs (8 adalimumab, 7 infliximab, and 3 etanercept) comprising 4039 patients randomized to TNFI biosimilars and 3905 to TNFI treatment were included...
July 5, 2021: Zeitschrift Für Rheumatologie
https://read.qxmd.com/read/21289933/influence-of-tumor-necrosis-factor-%C3%AE-in-rheumatoid-arthritis
#3
JOURNAL ARTICLE
Werner Kulp, Michael Corzillus, Wolfgang Greiner, Ludger Pientka, Uwe Siebert, Johann-Matthias von der Schulenburg, Jürgen Wasem
OBJECTIVE: Rheumatoid arthritis (RA) is the most prevalent inflammatory rheumatic disorder. It is a chronic and incurable disease that leads to painful inflammation, often irreversible joint damage, and eventually to functional loss. Conventional treatment is based on unspecific immunosuppressive agents, e.g. Methotrexate, Azathioprin or Gold. However, the longterm outcomes of these approaches have been poor with frequently ongoing inflammatory disease activity, functional decline, and temporary or permanent work disability...
December 21, 2005: GMS Health Technology Assessment
https://read.qxmd.com/read/16724372/therapies-for-peripheral-joint-disease-in-psoriatic-arthritis-a-systematic-review
#4
REVIEW
Enrique R Soriano, Neil J McHugh
Traditional drug treatments for psoriatic arthritis (PsA) include nonsteroidal antiinflammatory agents (NSAID) and disease modifying antirheumatic drugs (DMARD), although the evidence base for their effectiveness is not well established. This review was compiled from a comprehensive literature search of electronic bibliographic databases for all English publications that were systematic reviews, metaanalyses, randomized controlled trials, controlled trials, and observational studies. The evidence supports NSAID for symptom relief, although data are lacking for COX-2-specific agents...
July 2006: Journal of Rheumatology
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.